DD145266A5 - Verfahren zur herstellung von 6-methoxy-2-acetylnaphthalinoxim-derivaten - Google Patents
Verfahren zur herstellung von 6-methoxy-2-acetylnaphthalinoxim-derivaten Download PDFInfo
- Publication number
- DD145266A5 DD145266A5 DD79214687A DD21468779A DD145266A5 DD 145266 A5 DD145266 A5 DD 145266A5 DD 79214687 A DD79214687 A DD 79214687A DD 21468779 A DD21468779 A DD 21468779A DD 145266 A5 DD145266 A5 DD 145266A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- methoxy
- formula
- derivatives
- oxime
- prepared
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title claims description 9
- FKUMAWUBPURONA-UHFFFAOYSA-N n-[1-(6-methoxynaphthalen-2-yl)ethylidene]hydroxylamine Chemical class C1=C(C(C)=NO)C=CC2=CC(OC)=CC=C21 FKUMAWUBPURONA-UHFFFAOYSA-N 0.000 title claims description 4
- 101000588924 Anthopleura elegantissima Delta-actitoxin-Ael1a Proteins 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 8
- -1 oxime hydrochloride Chemical class 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 150000002923 oximes Chemical class 0.000 claims description 5
- 239000012458 free base Substances 0.000 claims description 4
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- GUWMQEUWBPJTNQ-UHFFFAOYSA-N 1-(6-methoxynaphthalen-2-yl)-n-(2-pyrrolidin-1-ylethoxy)ethanimine;hydrochloride Chemical compound Cl.C1=CC2=CC(OC)=CC=C2C=C1C(C)=NOCCN1CCCC1 GUWMQEUWBPJTNQ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 150000003840 hydrochlorides Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000000202 analgesic effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 230000001754 anti-pyretic effect Effects 0.000 description 5
- 239000002221 antipyretic Substances 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- GGWCZBGAIGGTDA-UHFFFAOYSA-N 1-(6-methoxynaphthalen-2-yl)ethanone Chemical class C1=C(C(C)=O)C=CC2=CC(OC)=CC=C21 GGWCZBGAIGGTDA-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- VKPPFDPXZWFDFA-UHFFFAOYSA-N 2-chloroethanamine Chemical compound NCCCl VKPPFDPXZWFDFA-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- BJKZQNPIHGBLIV-UHFFFAOYSA-N 2-[1-(6-methoxynaphthalen-2-yl)ethylideneamino]oxy-n,n-dimethylethanamine Chemical compound C1=C(C(C)=NOCCN(C)C)C=CC2=CC(OC)=CC=C21 BJKZQNPIHGBLIV-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- ZEHGKSPCAMLJDC-UHFFFAOYSA-M acetylcholine bromide Chemical compound [Br-].CC(=O)OCC[N+](C)(C)C ZEHGKSPCAMLJDC-UHFFFAOYSA-M 0.000 description 1
- 229940080018 acetylcholine injection Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7822836A FR2432506A1 (fr) | 1978-08-02 | 1978-08-02 | Nouveaux derives de 6-methoxy-2-acetylnaphtalene oxime, leur preparation et leur application en tant que medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
DD145266A5 true DD145266A5 (de) | 1980-12-03 |
Family
ID=9211492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DD79214687A DD145266A5 (de) | 1978-08-02 | 1979-07-30 | Verfahren zur herstellung von 6-methoxy-2-acetylnaphthalinoxim-derivaten |
Country Status (25)
Country | Link |
---|---|
US (1) | US4267334A (fr) |
JP (1) | JPS5555155A (fr) |
AR (1) | AR221502A1 (fr) |
AT (1) | AT367744B (fr) |
BE (1) | BE878019A (fr) |
BG (1) | BG36198A3 (fr) |
CA (1) | CA1128519A (fr) |
CH (1) | CH641773A5 (fr) |
CS (1) | CS215016B2 (fr) |
DD (1) | DD145266A5 (fr) |
DE (1) | DE2931319A1 (fr) |
EG (1) | EG14368A (fr) |
ES (1) | ES481855A1 (fr) |
FI (1) | FI70012C (fr) |
FR (1) | FR2432506A1 (fr) |
GB (1) | GB2045743B (fr) |
GR (1) | GR69826B (fr) |
IL (1) | IL57931A (fr) |
NL (1) | NL7905939A (fr) |
PL (1) | PL116462B1 (fr) |
PT (1) | PT70005A (fr) |
RO (1) | RO77339A (fr) |
SE (1) | SE446530B (fr) |
SU (1) | SU784763A3 (fr) |
YU (1) | YU41874B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58156006U (ja) * | 1982-04-13 | 1983-10-18 | 日本電気ホームエレクトロニクス株式会社 | 車輌室内換気装置 |
JPS61192912U (fr) * | 1985-05-25 | 1986-12-01 | ||
JPH0525285Y2 (fr) * | 1987-01-12 | 1993-06-25 | ||
JPS63173814U (fr) * | 1987-05-02 | 1988-11-11 | ||
WO2006047703A2 (fr) * | 2004-10-26 | 2006-05-04 | Sigma-Aldrich Co. | Synthese d'amino-acide, n-carboxyanhydrides |
GB2435830A (en) * | 2006-03-09 | 2007-09-12 | Del Dr Esteve S A Spain Lab | Oxime ether compounds for the treatment of conditions associated with food uptake |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3963778A (en) * | 1965-11-10 | 1976-06-15 | Bayer Aktiengesellschaft | Basic oximes and their preparation |
US3937841A (en) * | 1967-04-05 | 1976-02-10 | U.S. Philips Corporation | Treatment of depression |
-
1978
- 1978-08-02 FR FR7822836A patent/FR2432506A1/fr active Granted
-
1979
- 1979-06-06 ES ES481855A patent/ES481855A1/es not_active Expired
- 1979-07-20 US US06/059,249 patent/US4267334A/en not_active Expired - Lifetime
- 1979-07-26 YU YU1821/79A patent/YU41874B/xx unknown
- 1979-07-30 DD DD79214687A patent/DD145266A5/de not_active IP Right Cessation
- 1979-07-31 IL IL57931A patent/IL57931A/xx not_active IP Right Cessation
- 1979-07-31 PT PT70005A patent/PT70005A/fr unknown
- 1979-07-31 CH CH705179A patent/CH641773A5/fr not_active IP Right Cessation
- 1979-07-31 GR GR59743A patent/GR69826B/el unknown
- 1979-08-01 JP JP9860079A patent/JPS5555155A/ja active Granted
- 1979-08-01 CA CA333,015A patent/CA1128519A/fr not_active Expired
- 1979-08-01 EG EG466/79A patent/EG14368A/xx active
- 1979-08-01 RO RO7998336A patent/RO77339A/fr unknown
- 1979-08-01 NL NL7905939A patent/NL7905939A/nl not_active Application Discontinuation
- 1979-08-01 CS CS795313A patent/CS215016B2/cs unknown
- 1979-08-01 DE DE19792931319 patent/DE2931319A1/de not_active Ceased
- 1979-08-01 PL PL1979217508A patent/PL116462B1/pl unknown
- 1979-08-01 SE SE7906509A patent/SE446530B/sv not_active IP Right Cessation
- 1979-08-01 BG BG7944522A patent/BG36198A3/xx not_active Expired
- 1979-08-01 BE BE0/196559A patent/BE878019A/fr not_active IP Right Cessation
- 1979-08-01 AT AT0528779A patent/AT367744B/de not_active IP Right Cessation
- 1979-08-02 FI FI792414A patent/FI70012C/fi not_active IP Right Cessation
- 1979-08-02 SU SU792792753A patent/SU784763A3/ru active
- 1979-08-02 GB GB7926940A patent/GB2045743B/en not_active Expired
- 1979-08-02 AR AR277580A patent/AR221502A1/es active
Also Published As
Publication number | Publication date |
---|---|
SE7906509L (sv) | 1980-02-03 |
FR2432506B1 (fr) | 1981-07-24 |
PL116462B1 (en) | 1981-06-30 |
SE446530B (sv) | 1986-09-22 |
NL7905939A (nl) | 1980-02-05 |
FI70012C (fi) | 1986-09-12 |
GB2045743B (en) | 1982-09-02 |
EG14368A (en) | 1984-09-30 |
IL57931A (en) | 1982-08-31 |
JPS5555155A (en) | 1980-04-22 |
CA1128519A (fr) | 1982-07-27 |
US4267334A (en) | 1981-05-12 |
GB2045743A (en) | 1980-11-05 |
GR69826B (fr) | 1982-07-13 |
CS215016B2 (en) | 1982-06-25 |
FR2432506A1 (fr) | 1980-02-29 |
RO77339A (fr) | 1981-08-17 |
IL57931A0 (en) | 1979-11-30 |
YU41874B (en) | 1988-02-29 |
PT70005A (fr) | 1979-08-01 |
CH641773A5 (fr) | 1984-03-15 |
YU182179A (en) | 1983-04-30 |
JPS5748107B2 (fr) | 1982-10-14 |
AR221502A1 (es) | 1981-02-13 |
AT367744B (de) | 1982-07-26 |
DE2931319A1 (de) | 1980-02-14 |
BG36198A3 (en) | 1984-09-14 |
BE878019A (fr) | 1980-02-01 |
ES481855A1 (es) | 1980-02-16 |
FI792414A (fi) | 1980-02-03 |
FI70012B (fi) | 1986-01-31 |
SU784763A3 (ru) | 1980-11-30 |
PL217508A1 (fr) | 1980-03-24 |
ATA528779A (de) | 1981-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2634288C3 (fr) | ||
DE69219221T2 (de) | Vanadium Komplexe, ihre Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten | |
DE3047142C2 (de) | Basische 1,7,7-Trimethylbicyclo[2,2,1]heptyläther, Verfahren zur Herstellung derselben und diese enthaltende Arzneimittel | |
DE2362409C3 (de) | N,N'-(m-Phenylen)-dioxamidsäuren und deren Derivate, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten | |
CH635823A5 (de) | Verfahren zur herstellung von neuen 1-amidin-3-substituierten-phenylharnstoffen. | |
CH625243A5 (fr) | ||
DE3409801A1 (de) | Thiazolidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
DE2736784A1 (de) | N-substituierte und nichtsubstituierte hexahydro-6-canthinonderivate, verfahren zum herstellen derselben und diese derivate enthaltende pharmazeutische zusammensetzung | |
DE3334757A1 (de) | Piperazinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate | |
DE2720545C3 (de) | Derivate des 2,4-Diamino-6,7-dimethoxychinazolins, ihre Herstellung und pharmazeutische Mittel | |
DE2044172C3 (de) | Pyrrolderivate, ein Verfahren zu ihrer Herstellung und Arzneimittel | |
DE2802864A1 (de) | 3-isobutoxy-2-pyrrolidino-n-phenyl- n-benzylpropylamin, verfahren zu seiner herstellung und es enthaltende arzneimittel | |
DD145266A5 (de) | Verfahren zur herstellung von 6-methoxy-2-acetylnaphthalinoxim-derivaten | |
DE2128375C3 (de) | Basische substituierte Alkylidenamino-oxyalkyl-carbonsäureester, deren Säureadditionssalze, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate | |
DE2314335A1 (de) | Neue amide der apovincaminsaeure, deren salze, herstellung und medikamente, die diese enthalten | |
DE2900288A1 (de) | Aminoderivate von pyrazol eckige klammer auf 1,5-a eckige klammer zu s-triazin, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
DE69007422T2 (de) | 1-(4-Aminophenyl)-2-piperidinopropanon-Derivate, Verfahren zu deren Herstellung und therapeutische Verwendung. | |
DE2336671A1 (de) | Oxyessigsaeureaether von o-thymotinsaeureestern | |
DE2336670A1 (de) | Aminoaether von o-thymotinsaeureestern | |
DE69625226T2 (de) | Neue n-acetylierte 4-hydroxyphenylaminen derivate mit analgetischen eigenschaften sowie diese enthaltende arzneimittel | |
DE2705949C2 (de) | 4-(Benzoylamino)-piperidinderivate, ein Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel | |
DE2513136B2 (de) | N-(I -Benzylpiperid-4-yl)-benzamide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate | |
DD149063A5 (de) | Verfahren zur herstellung von p-chloracetophenonoximderivaten | |
DE2934166A1 (de) | 1,3-benzoxazin-2,4-dion-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
DE2614138A1 (de) | Neue benzothienylamino-(propyl und butyl)-ketone, verfahren zu ihrer herstellung und deren verwendung als therapeutika |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENJ | Ceased due to non-payment of renewal fee |